UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

S1563 Patient Voice on Adherence and Satisfaction Following Switch in Therapy to Trientine Tetrahydrochloride for Wilson Disease: The ASTRA Study

The American journal of gastroenterology, 2023-10, Vol.118 (10S), p.S1179-S1180

2023

Volltextzugriff (PDF)

A 2D model to study how secondary growth affects the self-supporting behaviour of climbing plants

PLoS computational biology, 2023-10, Vol.19 (10), p.e1011538-e1011538

2023

Volltextzugriff (PDF)

Hamilton-Jacobi-Bellman Equation for Control Systems With Friction

IEEE transactions on automatic control, 2021-12, Vol.66 (12), p.5651-5664

2021

Volltextzugriff (PDF)

Quality of Life and Burden of Disease in Italian Patients with Transfusion-Dependent Beta-Thalassemia

Journal of clinical medicine, 2021-12, Vol.11 (1), p.15

2021

Volltextzugriff (PDF)

WED-191 The impact on adherence and patient satisfaction following a switch to trientine tetrahydrochloride for the maintenance therapy in Wilson’s disease

Journal of hepatology, 2024-06, Vol.80, p.S725-S725

2024

Volltextzugriff (PDF)

Optimal control of plant root tip dynamics in soil

Bioinspiration & biomimetics, 2020-09, Vol.15 (5), p.56006-056006

2020

Volltextzugriff (PDF)

Active Cell Equalization Scheme for Performance Enhancing a Li-ion Capacitor Energy Management System

2022 7th Asia Conference on Power and Electrical Engineering (ACPEE), 2022, p.290-294

2022

Volltextzugriff (PDF)

Lactic Acid Bacteria in Durum Wheat Flour Are Endophytic Components of the Plant during Its Entire Life Cycle

Applied and Environmental Microbiology, 2015-10, Vol.81 (19), p.6736-6748

2015

Volltextzugriff (PDF)

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e0109137

2023

Volltextzugriff (PDF)

New pedotransfer approaches to predict soil bulk density using WoSIS soil data and environmental covariates in Mediterranean agro-ecosystems

The Science of the total environment, 2021-08, Vol.780, p.146609-146609, Article 146609

2021

Volltextzugriff (PDF)

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

Blood, 2023-11, Vol.142 (Supplement 1), p.6016-6016

2023

Volltextzugriff (PDF)

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Blood, 2023-11, Vol.142 (Supplement 1), p.5879-5879

2023

Volltextzugriff (PDF)

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood, 2023-11, Vol.142 (Supplement 1), p.1567-1567

2023

Volltextzugriff (PDF)

Prognostic Relevance of Minimal Residual Disease in Therapy Related and Secondary Acute Myeloid Leukemia Receiving CPX-351 or Fludarabine-Based Induction

Blood, 2022-11, Vol.140 (Supplement 1), p.8930-8931

2022

Volltextzugriff (PDF)

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

Blood, 2023-11, Vol.142 (Supplement 1), p.2218-2218

2023

Volltextzugriff (PDF)

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Blood, 2023-11, Vol.142 (Supplement 1), p.2918-2918

2023

Volltextzugriff (PDF)

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML

HemaSphere, 2023-08, Vol.7 (S3), p.e997112b-n/a

2023

Volltextzugriff (PDF)

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood, 2023-11, Vol.142 (Supplement 1), p.1536-1536

2023

Volltextzugriff (PDF)

P381: FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA‐NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE

HemaSphere, 2023-08, Vol.7 (S3), p.e7714084-n/a

2023

Volltextzugriff (PDF)

P530: CPX‐351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION

HemaSphere, 2023-08, Vol.7 (S3), p.e89713c5-n/a

2023

Volltextzugriff (PDF)

S217: POST‐TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION

HemaSphere, 2023-08, Vol.7 (S3), p.e4683875-n/a

2023

Volltextzugriff (PDF)

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Blood, 2020-11, Vol.136 (Supplement 1), p.32-33

2020

Volltextzugriff (PDF)

Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma

Blood, 2019-11, Vol.134 (Supplement_1), p.3231-3231

2019

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(34)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(35)
Tagungsberichte
(1)

Sprache

Englisch
(36)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(11)
Life Sciences & Biomedicine
(10)
Hematology
(5)
Humans
(5)
Middle Aged
(4)
Acute Myeloid Leukemia
(3)
Female
(3)
Male
(3)
Mutation
(3)
Adult
(2)
Environmental Sciences
(2)
Flow Cytometry
(2)
Hematopoietic Stem Cell Transplantation
(2)
Immunology
(2)
Immunophenotype
(2)
Leukemia, Myeloid, Acute - Genetics
(2)
Leukemia, Myeloid, Acute - Pathology
(2)
Oncology
(2)
Patients
(2)
Prognosis
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

S1563 Patient Voice on Adherence and Satisfaction Following Switch in Therapy to Trientine Tetrahydrochloride for Wilson Disease: The ASTRA Study

A 2D model to study how secondary growth affects the self-supporting behaviour of climbing plants

Hamilton-Jacobi-Bellman Equation for Control Systems With Friction

Quality of Life and Burden of Disease in Italian Patients with Transfusion-Dependent Beta-Thalassemia

WED-191 The impact on adherence and patient satisfaction following a switch to trientine tetrahydrochloride for the maintenance therapy in Wilson’s disease

Optimal control of plant root tip dynamics in soil

Active Cell Equalization Scheme for Performance Enhancing a Li-ion Capacitor Energy Management System

Lactic Acid Bacteria in Durum Wheat Flour Are Endophytic Components of the Plant during Its Entire Life Cycle

PB1742: FEASIBILITY AND EFFICACY OF A PEG-ASPARAGINASE-BASED TREATMENT PROTOCOL IN ELDERLY PHILADELPHIA-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS

New pedotransfer approaches to predict soil bulk density using WoSIS soil data and environmental covariates in Mediterranean agro-ecosystems

Mutational Burden in High Risk Genes Do Not Affect Remission Rates and MRD Clearance in Elderly AML Patients Receiving CPX-351 Induction

High Efficacy and Feasibility of a Full Pediatric Induction in Adults Aged up to 55 Years with Philadelphia-Negative Acute Lymphoblastic Leukemia

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Prognostic Relevance of Minimal Residual Disease in Therapy Related and Secondary Acute Myeloid Leukemia Receiving CPX-351 or Fludarabine-Based Induction

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Truly Refractory Hodgkin Lymphoma Patients Is Highly Effective and Responses Are Mediated By NK Cells

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells

P553: PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN‐LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V‐FLAI) IN THE INDUCTION THERAPY OF NON LOW‐RISK AML

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated with Expansion and Maturation of NK Cells

P381: FULL PEDIATRIC INDUCTION IN ADULTS AGED UP TO 55 YEARS WITH PHILADELPHIA‐NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA IS WELL TOLERATED AND RESULTS IN VERY HIGH CURE RATE

P530: CPX‐351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION

S217: POST‐TRANSPLANT NIVOLUMAB PLUS UNSELECTED AUTOLOGOUS LYMPHOCYTES IN REFRACTORY HODGKIN LYMPHOMA RESULTS IN VERY HIGH REMISSION RATE AND EXCELLENT SURVIVAL AND IT IS ASSOCIATED WITH NK CELL EXPANSION

Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation

Adoptive Cell Therapy and Immune Check Points Inhibitors As a Salvage Treatment for Patient Affected By Relapsed/Refractory Hodgkin's Lymphoma

Suchergebnisse filtern